Osimertinib,BI-3406
astrazeneca,Boehringer Ingelheim
['action i', 'sos1', 'bi-3406', 'thanks']
thanks for including our paper published in describing bi-3406, a potent and selective sos1-kras interaction inhibitor. #kras #aacr23 
Global Head of Cancer Research @Boehringer. Focus on improving the lives of cancer patients.